dulaglutide vs Semaglutide (Wegovy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: December 2030 · NCT07282041 (registry estimate)

Reported efficacy

Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 (met)

Result source: NCT01394952

Semaglutide (Wegovy)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT03574597 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 17,604 participants and a hard cardiovascular event primary endpoint. The primary endpoint was met: 569 participants receiving semaglutide versus 701 receiving placebo experienced a qualifying event, with a hazard ratio of 0.80 (95% CI 0.72–0.89; p<0.0001).

Reported efficacy

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)

Result source: NCT03574597

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdulaglutideSemaglutide (Wegovy)
LDL-C, % change—Trial running · NCT07282041—Not reported
Non-HDL-C, % change—Trial running · NCT07282041—Not reported
ApoB, % change—Trial running · NCT07282041—Not reported
Lp(a), % change—Trial running · NCT07282041—Not reported
3-point MACE (% with event)—Trial running · NCT07282041—Not reported

LDL-C, % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Wegovy)
—Not reported

Non-HDL-C, % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Wegovy)
—Not reported

ApoB, % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Wegovy)
—Not reported

Lp(a), % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Wegovy)
—Not reported

3-point MACE (% with event)

dulaglutide
—Trial running · NCT07282041
Semaglutide (Wegovy)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

dulaglutide
Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 NCT01394952 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Semaglutide (Wegovy)
Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 NCT03574597 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · Semaglutide (Wegovy)'s landscape